TY  - GEN
AU  - Eron,Joseph J
AU  - Young,Benjamin
AU  - Cooper,David A
AU  - Youle,Michael
AU  - Dejesus,Edwin
AU  - Andrade-Villanueva,Jaime
AU  - Workman,Cassy
AU  - Zajdenverg,Roberto
AU  - Fätkenheuer,Gerd
AU  - Berger,Daniel S
AU  - Kumar,Princy N
AU  - Rodgers,Anthony J
AU  - Shaughnessy,Melissa A
AU  - Walker,Monica L
AU  - Barnard,Richard J O
AU  - Miller,Michael D
AU  - Dinubile,Mark J
AU  - Nguyen,Bach-Yen
AU  - Leavitt,Randi
AU  - Xu,Xia
AU  - Sklar,Peter
TI  - Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
SN  - 1474-547X
PY  - 2010///0218
KW  - Adult
KW  - Anti-HIV Agents
KW  - adverse effects
KW  - Cholesterol, LDL
KW  - blood
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - HIV Infections
KW  - HIV-1
KW  - drug effects
KW  - Humans
KW  - Lopinavir
KW  - Male
KW  - Middle Aged
KW  - Pyrimidinones
KW  - Pyrrolidinones
KW  - RNA, Viral
KW  - Raltegravir Potassium
KW  - Ritonavir
KW  - Treatment Outcome
KW  - Viremia
KW  - physiopathology
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(09)62041-9
ER  -